Τίτλος:
An official European respiratory society statement on physical activity in COPD
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
This European Respiratory Society (ERS) statement provides a comprehensive overview on physical activity in patients with chronic obstructive pulmonary disease (COPD). A multidisciplinary Task Force of experts representing the ERS Scientific Group 01.02 ''Rehabilitation and Chronic Care'' determined the overall scope of this statement through consensus. Focused literature reviews were conducted in key topic areas and the final content of this Statement was agreed upon by all members. The current knowledge regarding physical activity in COPD is presented, including the definition of physical activity, the consequences of physical inactivity on lung function decline and COPD incidence, physical activity assessment, prevalence of physical inactivity in COPD, clinical correlates of physical activity, effects of physical inactivity on hospitalisations and mortality, and treatment strategies to improve physical activity in patients with COPD. This Task Force identified multiple major areas of research that need to be addressed further in the coming years. These include, but are not limited to, the disease-modifying potential of increased physical activity, and to further understand how improvements in exercise capacity, dyspnoea and self-efficacy following interventions may translate into increased physical activity. The Task Force recommends that this ERS statement should be reviewed periodically (e.g. every 5-8 years). © 2014 ERS.
Συγγραφείς:
Watz, H.
Pitta, F.
Rochester, C.L.
Garcia-Aymerich, J.
ZuWallack, R.
Troosters, T.
Vaes, A.W.
Puhan, M.A.
Jehn, M.
Polkey, M.I.
Vogiatzis, I.
Clini, E.M.
Toth, M.
Gimeno-Santos, E.
Waschki, B.
Esteban, C.
Hayot, M.
Casaburi, R.
Porszasz, J.
McAuley, E.
Singh, S.J.
Langer, D.
Wouters, E.F.M.
Magnussen, H.
Spruit, M.A.
Περιοδικό:
The European respiratory journal
Εκδότης:
European Respiratory Society
Λέξεις-κλειδιά:
beta adrenergic receptor stimulating agent; bronchodilating agent; long acting drug; placebo, ambulatory care; Article; behavior change; chronic obstructive lung disease; clinical assessment; daily life activity; disease association; disease exacerbation; disease severity; feedback system; forced expiratory volume; forced vital capacity; health status; hospitalization; human; medical society; mortality; oxygen therapy; patient counseling; physical activity; physical inactivity; physical performance; pulmonary rehabilitation; questionnaire; self concept; advisory committee; daily life activity; Europe; exercise; kinesiotherapy; motor activity; Pulmonary Disease, Chronic Obstructive, Activities of Daily Living; Advisory Committees; Europe; Exercise; Exercise Therapy; Humans; Motor Activity; Pulmonary Disease, Chronic Obstructive; Societies, Medical
DOI:
10.1183/09031936.00046814
